Targeting IL-23p19 in Inflammatory Bowel Disease: The Road Ahead
Abstract Selective interleukin-23p19 (IL-23p19) inhibition represents a major advance in the management of inflammatory bowel disease (IBD). Risankizumab, mirikizumab, and guselkumab – three monoclonal antibodies targeting the p19 subunit of IL-23 – have each completed Phase 3 clinical development programs in both Croh...